Cargando…

Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination

Understanding the T-cell responses involved in inhibiting COVID-19 severity is crucial for developing new therapeutic and vaccine strategies. Here, we characterized SARS-CoV-2 spike-specific CD8(+) T cells in vaccinees longitudinally. The BNT162b2 mRNA vaccine can induce spike-specific CD8(+) T cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Nogimori, Takuto, Suzuki, Koichiro, Masuta, Yuji, Washizaki, Ayaka, Yagoto, Mika, Ikeda, Mami, Katayama, Yuki, Kanda, Hidenori, Takada, Minoru, Minami, Shohei, Kobayashi, Takeshi, Takahama, Shokichi, Yoshioka, Yasuo, Yamamoto, Takuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845949/
https://www.ncbi.nlm.nih.gov/pubmed/36685601
http://dx.doi.org/10.3389/fimmu.2022.1081047
_version_ 1784871036718678016
author Nogimori, Takuto
Suzuki, Koichiro
Masuta, Yuji
Washizaki, Ayaka
Yagoto, Mika
Ikeda, Mami
Katayama, Yuki
Kanda, Hidenori
Takada, Minoru
Minami, Shohei
Kobayashi, Takeshi
Takahama, Shokichi
Yoshioka, Yasuo
Yamamoto, Takuya
author_facet Nogimori, Takuto
Suzuki, Koichiro
Masuta, Yuji
Washizaki, Ayaka
Yagoto, Mika
Ikeda, Mami
Katayama, Yuki
Kanda, Hidenori
Takada, Minoru
Minami, Shohei
Kobayashi, Takeshi
Takahama, Shokichi
Yoshioka, Yasuo
Yamamoto, Takuya
author_sort Nogimori, Takuto
collection PubMed
description Understanding the T-cell responses involved in inhibiting COVID-19 severity is crucial for developing new therapeutic and vaccine strategies. Here, we characterized SARS-CoV-2 spike-specific CD8(+) T cells in vaccinees longitudinally. The BNT162b2 mRNA vaccine can induce spike-specific CD8(+) T cells cross-reacting to BA.1, whereas the T-cell receptor (TCR) repertoire usages decreased with time. Furthermore the mRNA vaccine induced spike-specific CD8(+) T cells subpopulation expressing Granzyme A (GZMA), Granzyme B (GZMB) and Perforin simultaneously in healthy donors at 4 weeks after the second vaccination. The induced subpopulation was not maintained at 12 weeks after the second vaccination. Incorporating factors that efficiently induce CD8(+) T cells with highly cytotoxic activity could improve future vaccine efficacy against such variants.
format Online
Article
Text
id pubmed-9845949
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98459492023-01-19 Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination Nogimori, Takuto Suzuki, Koichiro Masuta, Yuji Washizaki, Ayaka Yagoto, Mika Ikeda, Mami Katayama, Yuki Kanda, Hidenori Takada, Minoru Minami, Shohei Kobayashi, Takeshi Takahama, Shokichi Yoshioka, Yasuo Yamamoto, Takuya Front Immunol Immunology Understanding the T-cell responses involved in inhibiting COVID-19 severity is crucial for developing new therapeutic and vaccine strategies. Here, we characterized SARS-CoV-2 spike-specific CD8(+) T cells in vaccinees longitudinally. The BNT162b2 mRNA vaccine can induce spike-specific CD8(+) T cells cross-reacting to BA.1, whereas the T-cell receptor (TCR) repertoire usages decreased with time. Furthermore the mRNA vaccine induced spike-specific CD8(+) T cells subpopulation expressing Granzyme A (GZMA), Granzyme B (GZMB) and Perforin simultaneously in healthy donors at 4 weeks after the second vaccination. The induced subpopulation was not maintained at 12 weeks after the second vaccination. Incorporating factors that efficiently induce CD8(+) T cells with highly cytotoxic activity could improve future vaccine efficacy against such variants. Frontiers Media S.A. 2023-01-04 /pmc/articles/PMC9845949/ /pubmed/36685601 http://dx.doi.org/10.3389/fimmu.2022.1081047 Text en Copyright © 2023 Nogimori, Suzuki, Masuta, Washizaki, Yagoto, Ikeda, Katayama, Kanda, Takada, Minami, Kobayashi, Takahama, Yoshioka and Yamamoto https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Nogimori, Takuto
Suzuki, Koichiro
Masuta, Yuji
Washizaki, Ayaka
Yagoto, Mika
Ikeda, Mami
Katayama, Yuki
Kanda, Hidenori
Takada, Minoru
Minami, Shohei
Kobayashi, Takeshi
Takahama, Shokichi
Yoshioka, Yasuo
Yamamoto, Takuya
Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination
title Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination
title_full Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination
title_fullStr Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination
title_full_unstemmed Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination
title_short Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination
title_sort functional changes in cytotoxic cd8+ t-cell cross-reactivity against the sars-cov-2 omicron variant after mrna vaccination
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845949/
https://www.ncbi.nlm.nih.gov/pubmed/36685601
http://dx.doi.org/10.3389/fimmu.2022.1081047
work_keys_str_mv AT nogimoritakuto functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination
AT suzukikoichiro functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination
AT masutayuji functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination
AT washizakiayaka functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination
AT yagotomika functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination
AT ikedamami functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination
AT katayamayuki functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination
AT kandahidenori functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination
AT takadaminoru functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination
AT minamishohei functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination
AT kobayashitakeshi functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination
AT takahamashokichi functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination
AT yoshiokayasuo functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination
AT yamamototakuya functionalchangesincytotoxiccd8tcellcrossreactivityagainstthesarscov2omicronvariantaftermrnavaccination